FinancialTOHO HOLDINGS CO.
Results of Operations: First Half of Fiscal Year Ending March 2018
1 Nov 20172 pages~4 min full read
TOHO HOLDINGS reported a 3.2% year-over-year decline in consolidated net sales to 595,962 million yen and a 28.6% drop in operating income to 5,458 million yen for the first half of fiscal year 2018.
See it on page 1The dispensing pharmacy business emerged as a growth driver, with net sales increasing 2.2% to 48,204 million yen and operating income surging 590.1% to 1,305 million yen.
See it on page 1The core pharmaceutical wholesaling segment experienced a 3.6% decline in net sales to 570,639 million yen, largely due to a contraction in the hepatitis C curative drug market.
See it on page 1The company launched the KYOSOMIRAI PHARMA generic drug brand, introducing 19 new products across 6 ingredients to capitalize on the industry's shift toward generic alternatives.
See it on page 1Despite the decline in primary financial metrics, the company outperformed its internal budget projections and maintained its original full-year earnings forecast.
See it on page 2Management is prioritizing operational efficiency and high-value service offerings, such as specialized voice-recognition software and examination reservation services, to mitigate market volatility.
See it on page 1TOHO HOLDINGS CO., LTD. reported consolidated financial results for the first half of the fiscal year ending March 2018, reflecting a period of strategic transition within the Japanese medical, healthcare, and nursing care sectors. Despite a broader decline in the prescription pharmaceuticals market—exacerbated by a significant contraction in the hepatitis C curative drug segment—the company outperformed its internal budget projections across all primary financial metrics. This performance was driven by a shift toward value-added services and operational efficiencies, even as year-over-year consolidated net sales decreased by 3.2% to 595,962 million yen and operating income fell by 28.6% to 5,458 million yen.
The pharmaceutical wholesaling business, which remains the company’s largest segment, faced headwinds with net sales of 570,639 million yen, a 3.6% decrease from the previous year. Conversely, the dispensing pharmacy business demonstrated strong growth, with net sales rising 2.2% to 48,204 million yen and operating income surging 590.1% to 1,305 million yen. These results were supported by the expansion of proprietary customer support systems and the launch of the KYOSOMIRAI PHARMA generic drug brand, which introduced 19 new products across 6 ingredients to align with the industry’s increasing reliance on generic alternatives.
Management continues to prioritize the optimization of personnel and organizational structures to enhance profitability. By focusing on high-value solutions for medical institutions and patients, such as specialized voice-recognition software and examination reservation services, the company aims to mitigate market volatility. Given the performance in the first half, the company has maintained its original full-year earnings forecasts, signaling confidence in its current business model and ongoing efforts to strengthen its market foundation.
